EMA plans guidance on process validation of biotechnology-derived active substances
This article was originally published in SRA
The European Medicines Agency is seeking stakeholder feedback on its plan to develop guidance on the process validation of biotechnology-derived active substances1. The agency's proposal is outlined in a concept paper, on which comments will be accepted until 31 August.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.